Floatz logo

Gemtuzumab Ozogamicin

Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)

Wake Forest University Health Sciencesantibody_drug_conjugatePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) cohort.

Asset / SponsorPhaseRating
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
Cytosin-Arabinosid
Alice Mims
Phase 3BBB
Idarubicine
Bruno C. Medeiros
Phase 2BBB
Fludarabine
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2BBB
ETOPOSIDE
Alice Mims
Phase 3BBB

View all 50 →

Same molecule, other indications

Gemtuzumab Ozogamicin is also rated in:

leukemiaDormant
BB
Indicative ·
69 / 100
View asset →
acute myeloid leukemiaDormant
BB
Indicative ·
67 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →